HISTOPATHOLOGY CONFIRMED SUPRATENTORIAL GBM AT FIRST RECURRENCE

Clinical trials for HISTOPATHOLOGY CONFIRMED SUPRATENTORIAL GBM AT FIRST RECURRENCE explained in plain language.

Never miss a new study

Get alerted when new HISTOPATHOLOGY CONFIRMED SUPRATENTORIAL GBM AT FIRST RECURRENCE trials appear

Sign up with your email to follow new studies for HISTOPATHOLOGY CONFIRMED SUPRATENTORIAL GBM AT FIRST RECURRENCE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for fighting back against aggressive brain cancer

Disease control Not yet recruiting

This study is testing a new drug combination for adults whose glioblastoma brain cancer has come back after initial treatment. The goal is to see if the experimental drug STAR-001, given with the blood pressure medicine spironolactone, is safe and can help control the tumor. Rese…

Matched conditions: HISTOPATHOLOGY CONFIRMED SUPRATENTORIAL GBM AT FIRST RECURRENCE

Phase: PHASE1, PHASE2 • Sponsor: Lantern Pharma Inc. • Aim: Disease control

Last updated Mar 23, 2026 15:15 UTC

HISTOPATHOLOGY CONFIRMED SUPRATENTORIAL GBM AT FIRST RECURRENCE

Get alerted when new HISTOPATHOLOGY CONFIRMED SUPRATENTORIAL GBM AT FIRST RECURRENCE trials appear

New hope for fighting back against aggressive brain cancer